Cantargia announced that Dr. David Liberg, member of Cantargia's management team, has been promoted to Chief Scientific Officer (CSO). Dr. Liberg joined Cantargia in 2015 and has since been part of Cantargia's management team and held the role of VP Research. He has over 25 years of experience in immunology and tumor biology research with a background from Active Biotech and Imperial College in London.

Dr. Liberg has played a key role in advancing the preclinical and translational development of Cantargia's lead asset nadunolimab (CAN04), as well as its second development project CAN10.